^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    T3011

    i
    Other names: T3011, MVR-T3011, B015
    Associations

    News

    Trials
    Company:
    ImmVira Pharma, Shanghai Pharma
    Drug class:
    PD1 inhibitor, IL-12 stimulant
    Related drugs:
    Associations

    News

    Trials
    1m
    A Clinical Study of T3011 Bladder Perfusion in Patients with High-risk Non-muscle-invasive Bladder Cancer (ChiCTR2500109273)
    P=N/A, N=15, Recruiting, Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center
    New trial
    |
    T3011
    2ms
    A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=30, Recruiting, ImmVira Pharma Co. Ltd | N=64 --> 30 | Trial completion date: Oct 2025 --> Jan 2027 | Trial primary completion date: Oct 2023 --> Sep 2026
    Enrollment change • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    ALK rearrangement
    |
    Keytruda (pembrolizumab) • T3011
    4ms
    A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC (clinicaltrials.gov)
    P2, N=160, Recruiting, ImmVira Pharma Co. Ltd | N=70 --> 160
    Enrollment change
    |
    T3011
    7ms
    A Study of T3011 in Patients With BCG-Unresponsive High Risk NMIBC (clinicaltrials.gov)
    P2, N=70, Recruiting, ImmVira Pharma Co. Ltd
    New P2 trial
    |
    T3011
    12ms
    A Clinical Study of T3011 in Subjects With Advanced Melanoma (clinicaltrials.gov)
    P1/2, N=42, Recruiting, Shanghai Pharmaceuticals Holding Co., Ltd | Trial primary completion date: Sep 2024 --> Sep 2025
    Trial primary completion date • Metastases
    |
    T3011
    over1year
    Preliminary results from a phase I study of T3011, an oncolytic HSV expressing IL-12 and anti-PD-1 antibody, for BCG-failure non-muscle-invasive bladder cancer (NMIBC) (ESMO 2024)
    Intravesical T3011 demonstrates a promising anti-tumor efficacy and an excellent safety profile in patients with high risk BCG-failure NMIBC.
    P1 data
    |
    IFNG (Interferon, gamma)
    |
    UroVysion™ Bladder Cancer Kit (UroVysion Kit)
    |
    T3011
    over1year
    Clinical Study of T3011 Intravesical Instillation for Treatment of NMIBC Patients (clinicaltrials.gov)
    P1, N=20, Recruiting, Fudan University
    New P1 trial
    |
    T3011
    almost2years
    Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=42, Active, not recruiting, ImmVira Pharma Co. Ltd | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • Metastases
    |
    T3011
    almost2years
    A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Liver Metastases From Colorectal Cancer (clinicaltrials.gov)
    P1, N=8, Not yet recruiting, China Medical University, China
    New P1 trial
    |
    Loqtorzi (toripalimab-tpzi) • Stivarga (regorafenib) • T3011
    almost2years
    T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma (clinicaltrials.gov)
    P2, N=68, Suspended, ImmVira Pharma Co. Ltd | Phase classification: P2a --> P2 | Trial completion date: Jan 2026 --> Jan 2027 | Not yet recruiting --> Suspended | Trial primary completion date: Dec 2025 --> Dec 2026
    Phase classification • Trial completion date • Trial suspension • Trial primary completion date • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600 • BRAF V600K • RAS mutation • BRAF V600E + BRAF V600K
    |
    Cotellic (cobimetinib) • T3011
    almost2years
    A Clinical Study of T3011 in Subjects With Advanced Melanoma (clinicaltrials.gov)
    P1/2, N=42, Recruiting, Shanghai Pharmaceuticals Holding Co., Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    T3011
    almost2years
    A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=68, Recruiting, Shanghai Pharmaceuticals Holding Co., Ltd | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    T3011